CLX 1205

Drug Profile

CLX 1205

Latest Information Update: 27 Oct 2005

Price : $50

At a glance

  • Originator Calyx Therapeutics (CEASED)
  • Class Antirheumatics
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 25 Oct 2005 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
  • 23 Aug 2000 Preclinical development for Rheumatoid arthritis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top